OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53

Background: Sorafenib (Nexavar(®)) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, the low efficacy and adverse effects at high doses limit the clinical application of sorafenib and strongly recommend its combination with other agents aiming at ameliorating...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Front Pharmacol
Main Authors: Omar, Hany A., Tolba, Mai F., Hung, Jui-Hsiang, Al-Tel, Taleb H.
Format: Artigo
Sprog:Inglês
Udgivet: Frontiers Media S.A. 2016
Fag:
Pharmacology
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5127788/
https://ncbi.nlm.nih.gov/pubmed/27965580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2016.00463
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker